Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-091350
Filing Date
2025-09-18
Accepted
2025-09-18 17:32:20
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 37550
2 EXHIBIT A tm2526392d1_ex99-a.htm EX-99.A 9780
3 EXHIBIT B tm2526392d1_ex99-b.htm EX-99.B 14195
  Complete submission text file 0001104659-25-091350.txt   63215
Mailing Address 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025
Business Address 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 650-681-8420
Sofinnova Venture Partners XI, L.P. (Filed by) CIK: 0001882303 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 99 HIGH STREET SUITE 2100 BOSTON MA 02110
Business Address 99 HIGH STREET SUITE 2100 BOSTON MA 02110 857-321-8020
Rapport Therapeutics, Inc. (Subject) CIK: 0002012593 (see all company filings)

EIN.: 880724208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94532 | Film No.: 251324444
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)